These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37794185)

  • 81. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8
    Watkins-Schulz R; Tiet P; Gallovic MD; Junkins RD; Batty C; Bachelder EM; Ainslie KM; Ting JPY
    Biomaterials; 2019 Jun; 205():94-105. PubMed ID: 30909112
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.
    Archilla-Ortega A; Domuro C; Martin-Liberal J; Muñoz P
    J Exp Clin Cancer Res; 2022 Feb; 41(1):62. PubMed ID: 35164813
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Small molecule inhibitors for cancer immunotherapy and associated biomarkers - the current status.
    Schlicher L; Green LG; Romagnani A; Renner F
    Front Immunol; 2023; 14():1297175. PubMed ID: 38022587
    [TBL] [Abstract][Full Text] [Related]  

  • 87. PI3K Isoform Immunotherapy for Solid Tumours.
    Scott J; Rees L; Gallimore A; Lauder SN
    Curr Top Microbiol Immunol; 2022; 436():369-392. PubMed ID: 36243853
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach.
    Lauder SN; Vanhaesebroeck B; Gallimore A
    Br J Cancer; 2021 Aug; 125(4):467-469. PubMed ID: 33824480
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Inhibition of DUSP18 impairs cholesterol biosynthesis and promotes anti-tumor immunity in colorectal cancer.
    Zhou X; Wang G; Tian C; Du L; Prochownik EV; Li Y
    Nat Commun; 2024 Jul; 15(1):5851. PubMed ID: 38992029
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies.
    Salmond RJ
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334623
    [TBL] [Abstract][Full Text] [Related]  

  • 91. X-CHIME enables combinatorial, inducible, lineage-specific and sequential knockout of genes in the immune system.
    LaFleur MW; Lemmen AM; Streeter ISL; Nguyen TH; Milling LE; Derosia NM; Hoffman ZM; Gillis JE; Tjokrosurjo Q; Markson SC; Huang AY; Anekal PV; Montero Llopis P; Haining WN; Doench JG; Sharpe AH
    Nat Immunol; 2024 Jan; 25(1):178-188. PubMed ID: 38012416
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The Inhibitors of Protein Tyrosine Phosphatase Nonreceptor Type 2 (PTPN2) as Potential Enhancers of Cancer Immunotherapy and Type 1 (PTPN1) as Treatment of Metabolic Diseases.
    Abdel-Magid AF
    ACS Med Chem Lett; 2022 Jan; 13(1):19-21. PubMed ID: 35059117
    [No Abstract]   [Full Text] [Related]  

  • 93. Haploinsufficiency in PTPN2 leads to early-onset systemic autoimmunity from Evans syndrome to lupus.
    Jeanpierre M; Cognard J; Tusseau M; Riller Q; Bui LC; Berthelet J; Laurent A; Crickx E; Parlato M; Stolzenberg MC; Suarez F; Leverger G; Aladjidi N; Collardeau-Frachon S; Pietrement C; Malphettes M; Froissart A; Bole-Feysot C; Cagnard N; Rodrigues Lima F; Walzer T; Rieux-Laucat F; Belot A; Mathieu AL
    J Exp Med; 2024 Sep; 221(9):. PubMed ID: 39028869
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment.
    Polak R; Zhang ET; Kuo CJ
    Nat Rev Cancer; 2024 Aug; 24(8):523-539. PubMed ID: 38977835
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Little ones can do big things: Small molecule inhibitors target PTPN2/PTPN1 for tumor immunotherapy.
    Wang J; Qin S; Zhang A
    MedComm (2020); 2024 Jun; 5(6):e567. PubMed ID: 38817652
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Ursonic acid from medicinal herbs inhibits PRRSV replication through activation of the innate immune response by targeting the phosphatase PTPN1.
    Yang Y; Gao Y; Sun H; Bai J; Zhang J; Zhang L; Liu X; Sun Y; Jiang P
    Vet Res; 2024 May; 55(1):67. PubMed ID: 38783392
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Site-Specifically Modified Peptide Inhibitors of Protein Tyrosine Phosphatase 1B and T-Cell Protein Tyrosine Phosphatase with Enhanced Stability and Improved In Vivo Long-Acting Activity.
    Zhang C; Yang X; Wu L; Liu F; Dong K; Guo C; Gong L; Dong G; Shi Y; Gu Z; Liu X; Liu S; Wu J; Su F
    ACS Pharmacol Transl Sci; 2024 May; 7(5):1426-1437. PubMed ID: 38751623
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Immunotherapeutic implications of negative regulation by protein tyrosine phosphatases in T cells: the emerging cases of PTP1B and TCPTP.
    Perez-Quintero LA; Abidin BM; Tremblay ML
    Front Med (Lausanne); 2024; 11():1364778. PubMed ID: 38707187
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features.
    Bourlon MT; Urbina-Ramirez S; Verduzco-Aguirre HC; Mora-Pineda M; Velazquez HE; Leon-Rodriguez E; Atisha-Fregoso Y; De Anda-Gonzalez MG
    Front Oncol; 2024; 14():1334845. PubMed ID: 38706600
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.